BOSTON, Nov. 22, 2016 /PRNewswire/ -- Leading life science real estate developer BioMed Realty today announced that Shire Human Genetic Therapies, Inc., a subsidiary of Shire, Plc, will become the next anchor tenant of its iconic 500 Kendall Street building in the heart of Kendall Square. The 12-year lease for 343,000 square feet of office space in the global life science center of Cambridge is an expansion of the existing presence of the biotechnology company, which is focused on serving people with rare diseases and other highly specialized conditions. Shire is expected to move into the building by early 2019, shortly after the scheduled lease expiration with the current tenant. "We're extremely pleased that Shire is expanding its Cambridge presence with us as a continued real estate partner," said Tim Schoen, CEO and President of BioMed Realty. "500 Kendall Street is one of our most well-known buildings, with its unmatched location in the heart of Kendall Square, providing the ideal space and location for a leading global company like Shire to continue its growth." Shire also occupies approximately 206,000 square feet at BioMed Realty's 650 East Kendall Street building. Extending into the new space at 500 Kendall Street is the next step for Shire's expansion of its Rare Disease Innovation Hub within Kendall Square, as the global company increases its Cambridge footprint immediately adjacent to 650 Kendall Street. Expanding into 500 Kendall Street will support the company's longer-term growth plans in Cambridge's thriving life science community.